Baillie Gifford & Co
PRCT icon

Baillie Gifford & Co’s Procept Biorobotics PRCT Stock Holding History

Baillie Gifford & Co’s Portfolio PRCT Stock Details PRCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.6M Sell
911,751
-61,751
-6% -$1.55M 0.02% 180
2026
Q1 		$24.3M Sell
973,502
-42,476
-4% -$1.2M 0.02% 174
2025
Q4 		$32M Buy
1,015,978
+157,147
+18% +$5.21M 0.03% 169
2025
Q3 		$30.7M Sell
858,831
-17,532
-2% -$801K 0.02% 172
2025
Q2 		$50.5M Buy
876,363
+562,479
+179% +$31.8M 0.04% 148
2025
Q1 		$18.3M Buy
+313,884
New +$21.4M 0.02% 184
2023
Q2 		– Sell
-435
Closed -$12.4K – 402
2023
Q1 		$12.4K Buy
435
+59
+16% +$2.08K ﹤0.01% 382
2022
Q4 		$15.6K Hold
376
– – ﹤0.01% 366
2022
Q3 		$16K Hold
376
– – ﹤0.01% 362
2022
Q2 		$12K Hold
376
– – ﹤0.01% 396
2022
Q1 		$13K Hold
376
– – ﹤0.01% 420
2021
Q4 		$9K Buy
+376
New +$13.9K ﹤0.01% 455

Other funds holding PRCT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Baillie Gifford & Co's PRCT Position: Q2 2026 in Review

Baillie Gifford & Co reduced its Procept Biorobotics (PRCT) stake by 6.3% in Q2 2026, selling an estimated $1.55M and leaving 911,751 shares worth $20.6M. The position accounts for 0.02% of the portfolio, ranked #180.

Baillie Gifford & Co first reported a position in PRCT in Q4 2021 and has held it in 12 quarters since. The position peaked at $50.5M in Q2 2025. 254 funds tracked by Wall St. Rank hold PRCT as of Q2 2026.

  • Baillie Gifford & Co held 911,751 shares of Procept Biorobotics worth $20.6M as of Q2 2026.
  • Baillie Gifford & Co sold 61,751 Procept Biorobotics shares in Q2 2026, an estimated $1.55M.
  • Procept Biorobotics made up 0.02% of Baillie Gifford & Co's portfolio in Q2 2026, its #180 holding.
  • Baillie Gifford & Co first reported a position in Procept Biorobotics in Q4 2021 and has held it in 12 quarters since.
  • Baillie Gifford & Co's Procept Biorobotics position peaked at $50.5M in Q2 2025.
  • 254 funds tracked by Wall St. Rank held Procept Biorobotics as of Q2 2026.

Based on Baillie Gifford & Co's 13F filing for Q2 2026, filed 6 Aug 2026.